FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OIVIB APPROV	AL
OMB Number:	3235-028
Estimated average bur	den
hours per response	0.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person Pande Atul				2. Issuer Name and Ticker or Trading Symbol Immunovant, Inc. [IMVT]								5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner Officer (give title below) Other (specify below)				
(Last) (First) (Middle) 320 W 37TH STREET, 6TH FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 01/10/2022								-	Officer (give)	inte below)	Ouic	(specify belo	w)
(Street) NEW YORK, NY 10018				4. If Amendment, Date Original Filed(Month/Day/Year))		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person				
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui							uriti	es Acquir	ired, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea			2A. Deemed Execution Date, any (Month/Day/Ye		ate, if	3. Transaction Code (Instr. 8)			4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)			Ownership Form:	Beneficial	
					(Year)	C	ode	V	Amount	(A) o		(Instr. 3 and 4)			Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
Common	Stock (1)		01/10/2022				1	A		21,726 (2)	A	\$ 0	61,926			D	
Common Stock												5,000			[By Trust	
Reminder.	Report on a s	separate line for each		- Deriv	ative Se	ecuriti	es Ac	P ir a quired	erson this curre	ns who res form are rently valid	ot root of OME	equired B contro					1474 (9-02)
Security	ative Conversion Date (Month/Day/Year) Execution Date, if Transaction of Derivative Code Securities (Month/Day/Year)		6. Date Expira	Date Exercisable and 7. Title a				d Amount of g Securities ad 4)		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	10. Ownersh Form of Derivativ Security: Direct (D or Indirect)	Beneficial Ownershi (Instr. 4)					
				Code	v	(A)	(D)	Date Exerci	sable	Expiration Date	1	Γitle	Amount or Number of Shares		(Instr. 4)	(Instr. 4)
Stock Option (right to buy)	\$ 7.94	01/10/2022		A	7	1,492		<u>(</u>	<u>4)</u>	01/10/20	32	Common Stock	n 71,492.00	\$ 0	208,973	D	

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Pande Atul 320 W 37TH STREET, 6TH FLOOR NEW YORK, NY 10018	X					

Signatures

/s/ Eva Renee Barnett, attorney-in-fact for Atul Pande	01/12/2022		
**Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents the number of shares underlying restricted stock units awards ("RSUs").

- (2) The RSUs vest over a period of two years, in a series of eight successive equal installments from the date of the award, subject to the Reporting Person providing continuous service to the Issuer as of each such date.
- (3) These shares are owned by a trust (the "Trust"). Certain members of the Reporting Person's immediate family are beneficiaries of the Trust.
- (4) Shares underlying the options vest over a period of two years, in a series of eight successive equal installments from the date of the award, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

IMMUNOVANT, INC. POWER OF ATTORNEY

(For Executing Form ID and Forms 3, 4 and 5)

Know all by these presents, that the undersigned hereby constitutes and appoints each of Jill Simon, Katherine Denby, Jenny Park O'Shanick and Jennifer Don of Cooley LLP, and Peter Salzmann a

- (1) Prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission (the "SEC") a Form ID, Uniform Application for Access C
- (2) Prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the SEC Forms 3, 4 and 5 (including amendments thereto and joint filing agreements in connecti
- (3) Do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to prepare and execute any such Form ID and Forms 3, 4 or 5 (including amendment

(4) Take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally r
The undersigned hereby grants to each such attorney in fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the
This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned'
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date written below.

Date: October 24, 2021

/s/ Atul Pande Atul Pande, M.D.